Arkenau HT, Saggese M, Lemech C. Advanced gastric cancer: Is there enough evidence to call second-line therapy standard? World J Gastroenterol 2012; 18(44): 6376-6378 [PMID: 23197882 DOI: 10.3748/wjg.v18.i44.6376]
Corresponding Author of This Article
Dr. Hendrik-Tobias Arkenau, PhD, Drug Development Unit, Sarah Cannon Research UK, University College London, 93 Harley Street, London W1G 6AD, United Kingdom. tobias.arkenau@sarahcannonresearch.co.uk
Article-Type of This Article
Field Of Vision
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/